Importantly, SorLA ab did not alter the proliferation of PDECs from HER2‐negative breast cancer (Fig. 5B), suggesting specific anti‐cancer effects for SorLA ab in HER2‐positive breast cancer. Here, ERBB2 is linked to breast carcinoma.